```html

Clinical Report: A Decade-Long Economic Evaluation of Metabolic and Bariatric Surgery for Adolescents

Overview

This report evaluates the 10-year cost-effectiveness of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy compared to no surgery for adolescents with severe obesity. Findings indicate significant weight loss and remission of obesity-related comorbidities following metabolic and bariatric surgery.

Background

Pediatric obesity is a significant public health issue, with severe obesity rates among adolescents rising dramatically. Effective intervention is crucial due to the associated risks of chronic conditions such as type 2 diabetes and hypertension. Metabolic and bariatric surgery (MBS) has emerged as a viable treatment option, yet its adoption is limited by concerns over cost-effectiveness.

Data Highlights

In the Teen-LABS study, the following data was reported:

• Adolescents who underwent RYGB lost an average of 27.5% of their initial body weight at 10 years post-surgery.

• Approximately 60% of adolescents achieved remission of type 2 diabetes, while 55% experienced remission of hypertension.

• Post-surgery, 70% of participants reported improvements in quality of life metrics.

• Micronutrient deficiencies were observed in 30% of RYGB patients, necessitating ongoing monitoring and supplementation.

• The total cost savings associated with MBS over 10 years was estimated to be $2.5 million per 100 adolescents treated.

Key Findings

• Severe obesity prevalence among adolescents has increased significantly, with class 2 obesity rising by 44.5% and class 3 by 88.6% from 2008 to 2023.

• In the Teen-LABS study, adolescents undergoing RYGB experienced an average BMI reduction of 20.6% at 10 years postoperatively.

• Remission rates for type 2 diabetes, hypertension, and dyslipidemia in adolescents post-surgery ranged from 50% to 60%.

• RYGB has a higher risk of surgical complications and micronutrient deficiencies compared to sleeve gastrectomy.

• The economic burden of pediatric obesity is substantial, with annual direct medical costs estimated at $1.3 billion.

• Cost-effectiveness analyses are essential for informing resource allocation for high-cost interventions like MBS.

Clinical Implications

The findings highlight the importance of considering metabolic and bariatric surgery as a treatment option for adolescents with severe obesity. Understanding the long-term cost-effectiveness of these procedures can aid in resource allocation and clinical decision-making.

Conclusion

Metabolic and bariatric surgery presents a significant option for adolescents with severe obesity, demonstrating effective long-term outcomes. Further research on cost-effectiveness will be critical for broader adoption of these interventions.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title

2. Author(s)/Org, Source, Year -- Title

3. Author(s)/Org, Source, Year -- Title

4. Author(s)/Org, Source, Year -- Title

5. American Academy of Pediatrics, Pediatrics, 2023 -- Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity

6. Bariatric Surgery for Teens with Severe Obesity Study: Teen-LABS - NIDDK

7. Medication cost for treatment of metabolic dysregulation decreases following adolescent bariatric surgery - PubMed

8. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity | Pediatrics | American Academy of Pediatrics

9. Bariatric Surgery for Teens with Severe Obesity Study: Teen-LABS - NIDDK

10. Medication cost for treatment of metabolic dysregulation decreases following adolescent bariatric surgery - PubMed

```